Genmab — Maj 2019
-
@Sukkeralf it already went through EMA earlier this year “Update of
sections 4.4. and 4.8 of the SmPC to add new
safety information on the recently identified risk
of Hepatitis B reactivation (HBV) -
The new DETER trial aparantly activated - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myelom https://ecog-acrin.org/trials/myeloma#title
-
abstract on ofatumumab @ American Academy of Neurology does not seem to tell us much new http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-001266.pdf http://indexsmart.mirasmart.com/AAN2019/SearchResults.php?q=ofatumumab
-
@Sukkeralf - Tak for link. Det glæder mig at den nyhed har været længe om at trænge ind, da jeg heller ikke lige på en studs kan se sammenhænget mellem ZW25/47 og DS-8201. Henviser du til at det er "bekræftelsen" af HER2 som target og en evt. mulig ligende aftale til ZYME der får ZYME til at stige ?
-
1070..here we come..:-(
-
Vi kan jo ikke blive ved med at sige pyt med at kursen ikke stiger - vi har bevæget os sidelæns i tre år ! Den slags investeringer gider jeg nu ikke. Personligt tror jeg stadig den manglende interesse dækker over en vis usikkerhed omkring peaksale.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind